<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02178306</url>
  </required_header>
  <id_info>
    <org_study_id>502.339</org_study_id>
    <nct_id>NCT02178306</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis</brief_title>
  <acronym>ESPRIT</acronym>
  <official_title>An Open-labeled, Placebo run-in, Multicentre Study to Investigate the Efficacy and Safety of Telmisartan (40 and 80 mg QD p.o.) in 3 Strata of Mild to Moderate Hypertensive Patients (Sitting Diastolic Blood Pressure ≥ 90 mmHg and ≤ 109 mmHg From Office Cuff Measurement) With Mild/Moderate or Severe Renal Impairment or Requiring Maintenance Hemodialysis. (ESPRIT Study = Efficacy and Safety in Patients With Renal Impairment Treated With Telmisartan)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy, in particular with regard to renal function of
      telmisartan at the doses of 40 mg and 80 mg in hypertensive patients with moderate to
      endstage renal impairment after 12 weeks of treatment
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <primary_completion_date type="Actual">April 2002</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in seated diastolic blood pressure (DBP) at trough</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in seated systolic blood pressure (SBP) at trough</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of response categories of blood pressure</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Categories:
BP normal
DBP control
DBP response
SBP response
BP high normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in proteinuria</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in electrolyte excretion</measure>
    <time_frame>12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the telmisartan plasma concentration-time curve</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of telmisartan</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak (Tmax) plasma concentrations of telmisartan</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of protein binding of telmisartan</measure>
    <time_frame>Day 7 and 12 weeks after start of treatment</time_frame>
    <description>equilibrium dialysis with subsequent determination of protein-bound telmisartan fraction</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan low dose</intervention_name>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan high dose</intervention_name>
    <description>patients switch to high dose if mean SBP &gt;= 85 mmHg after 4 weeks of treatment</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Run-in phase</description>
    <arm_group_label>Telmisartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Mild to moderate hypertension, sitting diastolic BP ≥ 90 mmHg and BP ≤ 109 mmHg at
             visit 2

          2. No increase of serum creatinine over 30% within 6 months before the trial

          3. Stable renal insufficiency with a serum creatinine between 200 and 600 µmol/l or
             maintenance of hemodialysis

          4. Stable proteinuria of at least 500 mg/24h

          5. No change in hemodialysis regimen within the last two months prior to visit 1

          6. 18 years of age or more

          7. Ability to provide written informed consent in accordance with good clinical practice
             and local registration

          8. Able to stop current antihypertensive therapy (ACE-Inhibitors or angiotensin II
             receptor subtype 1- Blocker) without risk to the patient

        Exclusion Criteria:

          1. Pre-menopausal women (last menstruation ≤ 1 year prior to start of run-in-phase) who:

               1. are not surgically sterile; and/or

               2. are nursing

               3. are of child-bearing potential and are NOT practicing acceptable means of birth
                  control, do NOT plan to continue using this method throughout the study and do
                  NOT agree to submit to periodic pregnancy testing during participation in studies
                  of ≥ 3-months duration. Acceptable methods of birth control include oral,
                  implantable or injectable contraceptives

          2. Known or suspected renovascular hypertension

          3. Mean sitting SBP ≥ 180 mmHg or mean sitting DBP ≥110 mmHg during any visit of the
             placebo run-in phase

          4. Hepatic dysfunction as defined by the following laboratory parameters:

             serum glutamate pyruvate transaminase (ALT) or serum glutamate oxaloacetate
             transaminase (AST) &gt; than 2 times the upper limit of normal range

          5. Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney, patients
             postrenal transplant or with only one kidney

          6. Clinically relevant hypo- or hyperkalaemia

          7. Uncorrected volume depletion

          8. Uncorrected sodium depletion

          9. Primary aldosteronism

         10. Hereditary fructose intolerance

         11. Biliary obstructive disorders

         12. Patients who have previously experienced symptoms characteristic of angioedema during
             treatment with ACE inhibitors or angiotensin II antagonists

         13. History of drug or alcohol abuse within 6 months

         14. Chronic administration of any medications known to affect blood pressure, except
             medication allowed by the protocol (ß-blocker, alpha-blocker, calcium antagonists,
             clonidine, minoxidil, and diuretics)

         15. Any investigational therapy within one month of signing the informed consent form

         16. Known hypersensitivity to any component of the formulation

         17. Has no contra-indication to a placebo run-in period (e.g. unstable angina within the
             past 3 months, stroke within the past 6 months or myocardial infarction or cardiac
             surgery within the past 3 months)

         18. Any other clinical condition which, in the opinion of the investigator, would not
             allow safe completion of the protocol and safe administration of telmisartan

         19. Compliance &lt; 70% during run-in period (defined by pill count)

         20. History of heart failure, malignancy, or any disorders requiring immunosuppressive
             therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2014</study_first_submitted>
  <study_first_submitted_qc>June 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2014</study_first_posted>
  <last_update_submitted>June 27, 2014</last_update_submitted>
  <last_update_submitted_qc>June 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

